Our Mission

We discovered the physics layer of biology.

InfiniGraph was founded on a discovery that changes the economics of drug development — every protein carries a physical signature that governs how it responds to drugs, and no existing tool could calculate it. We built HARMONY to change that.

Why We Exist

Drug discovery has a physics problem.

The pharmaceutical industry spends $2.6 billion and 12 years bringing the average drug to market — and 90% of candidates still fail in clinical trials. The root cause is not bad chemistry. It is an inability to predict, before spending hundreds of millions, how a protein will actually behave when a drug tries to bind to it. InfiniGraph built the equations to answer that question.

Physics Before Statistics

We do not train models on historical drug data and call it intelligence. Every result HARMONY produces is derived from the laws of physics — reproducible, traceable, and defensible in front of any scientific or regulatory audience.

Speed That Matters

In drug discovery, every month of delay is a month patients wait. HARMONY compresses the earliest and most critical stage of drug development from years to hours.

A Platform for Partners

HARMONY is not a bet on one drug. It is infrastructure that can run across any target, any disease, any indication. We are actively seeking pharma and biotech partners who see the same opportunity we do.

Leadership

Physics, medicine, and execution.

InfiniGraph is led by a founding team that has built category-defining companies, published in Nature, and invented the physics that makes HARMONY possible. Meet the full team →

Chase K. McMichael

Founder · CEO · Chief Science Officer

Founder, CEO, and Chief Science Officer. Developed the ARC-X platform and THE ONE equation, a discovery that transforms molecular detection and opens new frontiers in chemistry and quantum-inspired physics. Created HARMONY as the culmination of these breakthroughs. Inventor or co-inventor of 13 U.S. patents with numerous technical publications.

Lincoln D. Nadauld, MD, PhD

Chief Medical Officer

Practicing precision oncologist at Intermountain Health. First and senior author in Nature Genetics and Nature. Leads clinical development strategy and ClinVar-based target selection.

Michael Wiley, JD

General Counsel

Co-founder of Guardant Health (NASDAQ: GH, $3B+ market cap). Deep expertise in life science IP strategy, licensing, and commercialization. Oversees InfiniGraph's IP fortress and pharma partnership structure.